Recent studies into retatritide peptide highlight notable possibility for treating obesity and non-insulin dependent diabetes mellitus. The compound, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, appears to present enhanced body mass and glycemic control in contrast to existing medications. Additional patient studies are